Home/ Stocks/ NUVB

Nuvation Bio Inc.

NUVB XNYS

$6.60 +0.49 (+8.02%) ▲ 15-min delayed

Open

$6.30

High

$6.63

Low

$6.21

Volume

5.77M

Market Cap

$2.15B

About Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 305 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$83.23M	$5.40M	$0.02
FY 2025	$62.90M	$-204,627,000	$-0.60
Q3 2025	$13.12M	$-55,792,000	$-0.16
Q2 2025	$4.83M	$-59,007,000	$-0.17

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for NUVB yet. Check out our latest market news or earnings calendar.

Get NUVB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Nuvation Bio Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.